Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conjugated Proteins02:50

Conjugated Proteins

20.2K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
20.2K
Vaccinations01:51

Vaccinations

45.8K
Overview
45.8K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

461
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
461

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Choosing the Right Extracellular Vesicle: Cross-Kingdom Immunological Functions Linking Molecular Mechanisms to Therapeutic Applications.

Biomolecules·2026
Same author

A non-conjugated peptide-adjuvant system of synthetic peptide-vaccine elicited potent antibody response and opsonic protection against clinical GAS strains.

Bioorganic chemistry·2026
Same author

Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities.

NPJ vaccines·2026
Same author

Veterinary Forensic Pathology in the Investigation of Animal Cruelty: Post-Mortem Insights, Forensic Tools, Case Studies, and Legal Perspectives.

Animals : an open access journal from MDPI·2026
Same author

The Collaborative Collapse: Bile Acid Dysmetabolism as a Central Pathogenic Driver in Canine and Feline Multi-Systemic Disorders-From Mechanisms to Precision Therapeutics.

Veterinary sciences·2026
Same author

Development of a Novel Polyleucine-Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus.

Small (Weinheim an der Bergstrasse, Germany)·2026

Related Experiment Video

Updated: Oct 9, 2025

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.7K

Current Prospects in Peptide-Based Subunit Nanovaccines.

Prashamsa Koirala1, Sahra Bashiri1, Istvan Toth2,3,4

  • 1School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

Methods in Molecular Biology (Clifton, N.J.)
|December 17, 2021
PubMed
Summary
This summary is machine-generated.

Peptide vaccines, using tiny nanoparticles, offer a safer and more effective way to stimulate immunity against diseases. This nanotechnology approach overcomes limitations of traditional vaccines.

Keywords:
AdjuvantsImmunogenicityNanoparticlesNanotechnologyPathogensPeptidesSubunit vaccineVaccination

More Related Videos

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.7K
Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

1.9K

Related Experiment Videos

Last Updated: Oct 9, 2025

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.7K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.7K
Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

1.9K

Area of Science:

  • Immunology and Nanotechnology
  • Vaccine Development

Background:

  • Classical vaccines face challenges like adverse immune reactions and manufacturing issues.
  • Peptide antigens offer a safer alternative but require effective delivery systems and adjuvants.

Purpose of the Study:

  • To review advances in nanotechnology for peptide vaccine delivery.
  • To highlight nano-sized platforms enhancing peptide antigen immunogenicity.

Main Methods:

  • Exploration of nanotechnology applications in vaccine formulation.
  • Review of various nanoparticle compositions for antigen delivery.

Main Results:

  • Nanotechnology significantly boosts the immunogenicity of peptide vaccines.
  • Nano-formulations effectively induce both cellular and humoral immune responses.

Conclusions:

  • Nanotechnology presents a promising strategy for developing next-generation peptide vaccines.
  • Nano-delivery systems improve the efficacy and safety profile of subunit vaccines.